Comparison of antiangiogenic agents (ranibizumab, aflibercept, bevacizumab and ziv-aflibercept) in the therapeutic response to the exudative form of age-related macular degeneration according to the treat-and-extend protocol- true head-to-head study.
Tereza Cristina Moreira KanadaniNeiffer RabeloDenise TakahashiLucas MagalhãesMichel FarahPublished in: International journal of retina and vitreous (2024)
Results indicate that over 2 years, Intravitreal aflibercept on T&E provided better visual and anatomical improvements when compared to other drugs used in this study with significantly fewer injections.